AstraZeneca PLC (AZN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $286.07B
Last updated: Nov 17, 2026 at 11:05 AM ET
AstraZeneca PLC (AZN) Financials: Revenue, Profit and Cash Flow
AstraZeneca reported revenue of $58.74B for the fiscal year ended Dec 31, 2025, up 8.6% from the year before. That year, net income was $10.26B with a net margin of 17.5%, operating cash flow was $14.57B and free cash flow was $8.67B. The quarter ended Sep 30, 2026 had revenue of $15.99B and net income of $3.08B.
Revenue and Margins
The operating margin was 23.4% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $23.00B, a compound annual rate of 11.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $58.74B | +8.6% | 81.9% | 23.4% | 17.5% |
| Dec 2024 | $54.07B | +18.0% | 81.1% | 18.5% | 13.0% |
| Dec 2023 | $45.81B | +3.3% | 82.0% | 17.9% | 13.0% |
| Dec 2022 | $44.35B | +18.5% | 72.1% | 8.5% | 7.4% |
| Dec 2021 | $37.42B | +40.6% | 66.8% | 2.8% | 0.3% |
| Dec 2020 | $26.62B | +9.2% | 80.1% | 19.4% | 12.0% |
| Dec 2019 | $24.38B | +10.4% | 79.8% | 12.0% | 5.5% |
| Dec 2018 | $22.09B | -1.7% | 77.7% | 15.3% | 9.8% |
| Dec 2017 | $22.46B | -2.3% | 80.8% | 16.4% | 13.4% |
| Dec 2016 | $23.00B | N/A | 82.1% | 21.3% | 15.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 45.7% from the year before. In the quarter ended Sep 2026, net income rose 21.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B | $24.38B | $22.09B | $22.46B | $23.00B |
| Cost of revenue | $10.63B | $10.21B | $8.27B | $12.39B | $12.44B | $5.30B | $4.92B | $4.94B | $4.32B | $4.13B |
| Gross profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B | $19.46B | $17.15B | $18.15B | $18.88B |
| Research and development | $14.23B | $13.58B | $10.94B | $9.76B | $9.74B | $5.99B | $6.06B | $5.93B | $5.76B | $5.89B |
| Operating income | $13.74B | $10.00B | $8.19B | $3.76B | $1.06B | $5.16B | $2.92B | $3.39B | $3.68B | $4.90B |
| Net income | $10.26B | $7.04B | $5.96B | $3.29B | $112.00M | $3.20B | $1.33B | $2.15B | $3.00B | $3.50B |
| EBITDA | $19.83B | $15.44B | $13.42B | $9.09B | $5.11B | $8.08B | $6.71B | $7.11B | $6.62B | $7.28B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.99B | $15.38B | $15.29B | $15.50B | $15.19B | $14.46B | $13.59B | $13.59B | $14.89B | $13.56B | $12.94B | $12.68B |
| Gross profit | $11.93B | $12.86B | $12.61B | $12.38B | $12.39B | $11.98B | $11.35B | $11.35B | $12.17B | $10.48B | $10.76B | $10.46B |
| Operating income | $4.32B | $3.16B | $4.25B | $2.98B | $3.58B | $3.51B | $3.67B | $3.67B | $2.04B | $2.11B | $2.75B | $3.12B |
| Net income | $3.08B | $2.51B | $3.08B | $2.33B | $2.53B | $2.45B | $2.92B | $2.92B | $1.50B | $1.43B | $1.93B | $2.18B |
Balance Sheet
As of Dec 2025, total debt of $28.28B exceeded cash and equivalents by $22.57B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $114.07B | $104.03B | $101.12B | $96.48B | $105.36B | $66.73B | $61.38B | $60.65B | $63.35B | $62.53B |
| Current assets | $28.72B | $25.83B | $25.05B | $22.59B | $26.24B | $19.54B | $15.56B | $15.59B | $13.15B | $13.26B |
| Cash and equivalents | $5.71B | $5.49B | $5.84B | $6.17B | $6.33B | $7.83B | $5.37B | $4.83B | $3.32B | $5.02B |
| Total liabilities | $65.36B | $63.16B | $61.95B | $59.42B | $66.08B | $51.09B | $46.78B | $46.61B | $46.71B | $45.86B |
| Short-term debt | $3.57B | $2.50B | $5.40B | $5.45B | $1.80B | $2.39B | $2.01B | $1.78B | $2.27B | $2.33B |
| Long-term debt | $24.71B | $26.51B | $22.36B | $22.96B | $28.13B | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $48.67B | $40.79B | $39.14B | $37.04B | $39.27B | $15.62B | $13.13B | $12.47B | $14.96B | $14.85B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $119.71B | $115.70B | $114.02B | $114.07B | $114.46B | $112.42B | $106.25B | $106.25B | $104.03B | $104.92B | $104.34B | $102.29B |
| Total liabilities | $67.99B | $65.39B | $66.63B | $65.36B | $68.48B | $67.61B | $65.12B | $65.12B | $63.16B | $64.12B | $64.74B | $64.79B |
| Cash and equivalents | $7.92B | $4.89B | $7.56B | $5.71B | $8.14B | $7.06B | $5.23B | $5.23B | $5.49B | $4.80B | $6.92B | $7.84B |
| Shareholder equity | $51.64B | $50.24B | $47.33B | $48.67B | $45.89B | $44.72B | $41.04B | $41.04B | $40.79B | $40.72B | $39.51B | $37.45B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 59.5% of operating cash flow. Dividends came to 57.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.57B | $11.86B | $10.35B | $9.81B | $5.96B | $4.80B | $2.97B | $2.62B | $3.58B | $4.14B |
| Capital expenditures | $5.91B | $4.59B | $3.78B | $2.57B | $2.20B | $2.61B | $2.46B | $1.37B | $1.62B | $2.31B |
| Free cash flow | $8.67B | $7.28B | $6.57B | $7.24B | $3.76B | $2.19B | $509.00M | $1.25B | $1.96B | $1.83B |
| Dividends paid | $4.97B | $4.63B | $4.48B | $4.36B | $3.86B | $3.57B | $3.59B | $3.48B | $3.52B | $3.56B |
| Investing cash flow | -$6.81B | -$7.98B | -$4.06B | -$2.96B | -$11.06B | -$285.00M | -$657.00M | $963.00M | -$2.33B | -$3.97B |
| Financing cash flow | -$7.54B | -$4.00B | -$6.57B | -$6.82B | $3.65B | -$2.20B | -$1.76B | -$2.04B | -$2.94B | -$1.32B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.66B | $2.89B | $3.36B | $2.43B | $5.13B | $3.39B | $3.71B | $3.71B | $2.91B | $3.38B | $3.08B | $2.49B |
| Capital expenditures | $666.87M | $752.85M | $1.54B | $1.05B | $1.73B | $1.92B | $969.00M | $969.00M | $955.00M | $1.36B | $668.00M | $1.60B |
| Free cash flow | $3.99B | $2.13B | $1.82B | $1.38B | $3.41B | $1.46B | $2.74B | $2.74B | $1.95B | $2.02B | $2.42B | $881.00M |
Frequently Asked Questions About AZN
What is AstraZeneca's annual revenue?
AstraZeneca reported revenue of $58.74B for the fiscal year ended Dec 31, 2025.
How fast is AstraZeneca's revenue growing?
Revenue was up 8.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 9.8%.
Is AstraZeneca profitable?
Yes. AstraZeneca reported net income of $10.26B for the fiscal year ended Dec 31, 2025, with a net margin of 17.5%.
How much free cash flow does AZN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $14.57B minus capital expenditures of $5.91B produced free cash flow of $8.67B.
How much debt does AstraZeneca have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $24.71B, short-term debt of $3.57B and cash and equivalents of $5.71B.
AZN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts